Update to FDA’s Risk Evaluation and Mitigation Strategy for Mifepristone on Dec. 16, 2021, Eliminating In-Person Dispensing Requirement
FDA Lifts In-Person Dispensing Requirement for Mifepristone Abortion Pill.
Vol. 135 No. 8
FDA Lifts In-Person Dispensing Requirement for Mifepristone Abortion Pill.
SEC Provides Analytical Tools for Assessing Digital Assets.
Solicitor General Issues Guidance On Administrative Judges.